Insider · CIK 0001807910

Voliotis Dimitris

Reports to the SEC for 2 companies · CARLTON SOUTH, VICTORIA, NY

sec.gov

Transactions

Companies

Filings

CIK

0001807910

Forms 4 and 5

Insider transactions

21 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-02-14	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−534 sh	$50.16	−$26.8K	16,045
2022-02-14	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−67 sh	$50.75	−$3,400.062	15,978
2022-02-10	ZNTLZentalis Pharmaceuticals, Inc.A Award	SVP, Clinical Development	AAward	+10.3K sh	—	—	16,579
2022-02-10	ZNTLZentalis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	SVP, Clinical Development	AAward	+24.2K sh	—	—	24,234
2022-01-20	ZNTLZentalis Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Clinical Development	MExercise/Conversion	+10K sh	$18.00	+$180K	16,250
2022-01-20	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−8,343 sh	$60.52	−$505K	7,907
2022-01-20	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−1,657 sh	$61.21	−$101K	6,250
2022-01-20	ZNTLZentalis Pharmaceuticals, Inc. · Stock OptionM Exercise/Conversion	SVP, Clinical Development	MExercise/Conversion	−10K sh	—	—	124,949
2022-01-19	ZNTLZentalis Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Clinical Development	MExercise/Conversion	+10K sh	$18.00	+$180K	16,250
2022-01-19	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−7,889 sh	$60.55	−$478K	8,361
2022-01-19	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−1,556 sh	$61.51	−$95.7K	6,805
2022-01-19	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−555 sh	$62.24	−$34.5K	6,250
2022-01-19	ZNTLZentalis Pharmaceuticals, Inc. · Stock OptionM Exercise/Conversion	SVP, Clinical Development	MExercise/Conversion	−10K sh	—	—	134,949
2022-01-18	ZNTLZentalis Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Clinical Development	MExercise/Conversion	+10K sh	$18.00	+$180K	16,250
2022-01-18	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−3,409 sh	$61.70	−$210K	12,841
2022-01-18	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−3,294 sh	$62.34	−$205K	9,547
2022-01-18	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−1,997 sh	$63.48	−$127K	7,550
2022-01-18	ZNTLZentalis Pharmaceuticals, Inc.S Sale	SVP, Clinical Development	SSale	−1,300 sh	$64.66	−$84.1K	6,250
2022-01-18	ZNTLZentalis Pharmaceuticals, Inc. · Stock OptionM Exercise/Conversion	SVP, Clinical Development	MExercise/Conversion	−10K sh	—	—	144,949
2021-02-11	ZNTLZentalis Pharmaceuticals, Inc.A Award	SVP, Clinical Development	AAward	+6,250 sh	—	—	6,250
2021-02-11	ZNTLZentalis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	SVP, Clinical Development	AAward	+18.8K sh	—	—	18,750

Recent filings

Accepted (ET)
Feb 144
Voliotis Dimitris0001725160-22-000035
SEC(opens sec.gov)
Jan 204
Voliotis Dimitris0001725160-22-000015
SEC(opens sec.gov)
Feb 164
Voliotis Dimitris0001725160-21-000037
SEC(opens sec.gov)

Companies

Address

SUITE 1 LEVEL 3, 62 LYGON STREET

CARLTON SOUTH, VICTORIA, NY, 3053